Regulus Therapeutics Inc. (RGLS)

Market Cap	148.61M
Revenue (ttm)	n/a
Net Income (ttm)	-30.04M
Shares Out	65.47M
EPS (ttm)	-1.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,798
Open	2.270
Previous Close	2.220
Day's Range	2.170 - 2.290
52-Week Range	1.080 - 3.790
Beta	1.55
Analysts	Strong Buy
Price Target	7.25 (+216.59%)
Earnings Date	May 9, 2024

About RGLS

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was inco...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 4, 2012
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: RGLS

Analyst Forecast

According to 4 analysts, the average rating for RGLS stock is "Strong Buy." The 12-month stock price forecast is $7.25, which is an increase of 216.59% from the latest price.

Price Target

$7.25

(216.59% upside)

Analyst Consensus: Strong Buy